BeOne Medicines (ONC) Interest Expenses (2015 - 2026)
BeOne Medicines (ONC) reported Interest Expenses of $32.9 million for Q1 2026, up 369.68% year-over-year from $7.0 million in Q1 2025, and up 369.68% on a QoQ basis from $7.0 million in Q1 2025.
BeOne Medicines (ONC) has 4 years of Interest Expenses data on file, last reported at $32.9 million in Q1 2026.
- Quarterly Interest Expenses rose 369.68% year-over-year to $32.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.9 million (up 369.68% YoY) and the FY2025 annual result came in at $58.2 million, up 167.07% from the prior year.
- Interest Expenses improved to $32.9 million in Q1 2026 per ONC's latest filing, from $7.0 million in the prior quarter.
- Across five years, Interest Expenses topped out at $32.9 million in Q1 2026 and bottomed at $7.0 million in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 12.90 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | -332,000.00 |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 69.29 Mn |
| 10 | BeOne Medicines | - | - | 1.35 Bn | 32.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.89 Mn |
| Mar 31, 2026 | 32.89 Mn |
| Mar 31, 2025 | 7.00 Mn |
| Mar 31, 2025 | 7.00 Mn |
| Sep 30, 2016 | 284,000.00 |
| Sep 30, 2016 | 284,000.00 |
| Jun 30, 2016 | 141,000.00 |
| Jun 30, 2016 | 141,000.00 |
| Mar 31, 2016 | 204,000.00 |
| Mar 31, 2016 | 204,000.00 |
| Sep 30, 2015 | 300,000.00 |
| Sep 30, 2015 | 300,000.00 |
| Jun 30, 2015 | 273,000.00 |
| Jun 30, 2015 | 273,000.00 |
| Mar 31, 2015 | 267,000.00 |
| Mar 31, 2015 | 267,000.00 |